NASDAQ$BTAI
Bioxcel Therapeutics Inc · Q4 2021 earnings
Q4 2021 earnings · · Investor relations
Briefing
BioXcel Therapeutics reported its financial results for the fourth quarter and full year ended December 31, 2021, highlighting the near approval of BXCL501 and the progression of Alzheimer's and MDD programs.
BioXcel Therapeutics reported a net loss of $26.1 million for the fourth quarter of 2021, compared to a net loss of $21.1 million for the same period in 2020. As of December 31, 2021, cash and cash equivalents totaled approximately $233.0 million.
- Nearing potential approval for BXCL501, focusing on launch readiness.
- Initiated TRANQUILITY II AND III pivotal Phase 3 trials for BXCL501 in acute treatment of agitation associated with Alzheimer’s disease
- Submitted IND to evaluate BXCL501 as adjunctive treatment for major depressive disorder (MDD)
- Demonstrated encouraging composite response rates for BXCL701 in combination with KEYTRUDA® for mCRPC in SCNC and adenocarcinoma cohorts
Headline financials
Revenue & EPS history
Bioxcel Therapeutics · Revenue · Quarterly
$0
Revenue by segment
Bioxcel Therapeutics · $206K total across 1 segment · Q1 2026
- IGALMI$206K—100.0%
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q4 2021
-3.1%
Avg return
Earnings day
-5.5%
Avg return
5 days after
-9.4%
Avg return
30 days after
30%
10 / 33 earnings
Positive
+38.7%
Q3 2022
Best reaction
-44.1%
Q2 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | -5.6% | -8.7% | — | |
| Q1 2026 | -5.8% | -9.9% | -5.0% | |
| Q3 2025 | -16.0% | -9.4% | -0.5% | |
| Q2 2025 | +6.5% | -14.4% | -47.0% | |
| Q1 2025 | +0.0% | -4.8% | +6.8% | |
| Q4 2024 | +6.0% | -11.9% | -14.2% | |
| Q3 2024 | -8.2% | -2.6% | -33.4% | |
| Q2 2024 | -1.0% | -20.5% | -35.9% | |
| Q1 2024 | -1.4% | +0.5% | -33.3% | |
| Q4 2023 | -1.0% | -7.6% | -3.8% | |
| Q3 2023 | -20.1% | -25.0% | -41.2% | |
| Q2 2023 | -44.1% | -41.5% | -54.3% | |
| Q1 2023 | +17.7% | +18.6% | -9.6% | |
| Q4 2022 | -27.2% | -28.3% | -39.1% | |
| Q3 2022 | +38.7% | +41.1% | +49.2% | |
| Q2 2022 | -9.7% | -5.9% | -9.4% | |
| Q1 2022 | -10.6% | -6.5% | -6.7% | |
| Q4 2021 | -8.3% | -20.3% | -9.4% | |
| Q3 2021 | -2.4% | -19.7% | -35.5% | |
| Q2 2021 | +2.2% | -1.6% | +19.3% | |
| Q1 2021 | +8.1% | +3.1% | +27.2% | |
| Q4 2020 | +3.8% | +2.0% | -20.7% | |
| Q3 2020 | -4.1% | -8.6% | -23.8% | |
| Q2 2020 | -4.7% | -6.3% | +0.5% | |
| Q1 2020 | +0.1% | +9.6% | +6.7% | |
| Q4 2019 | -3.9% | -39.8% | -35.5% | |
| Q3 2019 | +12.4% | +40.6% | +48.3% | |
| Q2 2019 | -15.1% | -7.5% | +2.6% | |
| Q1 2019 | +12.8% | +9.4% | +5.3% | |
| Q4 2018 | -6.6% | +12.3% | +23.1% | |
| Q3 2018 | -7.9% | -12.6% | -21.8% | |
| Q2 2018 | -1.8% | -9.6% | -8.5% | |
| Q1 2018 | -4.9% | +3.6% | -1.9% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro